Overall Survival Progression-Free-Survival
Variables      HR          95%CI           P-value      HR          95%CI        P-value
Age > 60 years    1.111   1.024-1.428      <0.008  
Extra nodal sites-R > 1    1.090   0.918-1.285       0.8    1.235    0.809-1.168       0.4
LDH    1.000   0.999-1.007       0.7    1.050    1.000-1.232      0.07
LDH-R    1.523   1.001-1.812    <0.05    1.204    0.838-1.408      0.7
IPI ≥ 2    1.039   0.962-1.935       0.8    1.035    0.965-1.672      0.4
IPI-R > 2    1.178   0.849-1.308       0.6    1.354    0.738-1.944      0.2
CR prior to transplant   0.679   0.472-1.001       0.1    0.656    0.572-1.001      0.07
ALC-15 ≥ 500 cells/µl    0.424   0.236-0.617     <0.0004    0.608   0.466-0.804     <0.02
AMC-15 ≥ 600 cell/µl   2.177    1.459-2.861     <0.002    1.525   1.000-1.904       0.06
ALC/AMC-15 ratio ≥ 1   0.220    0.089-0.540      <0.0001    0.171  0.115-0.349      <0.0001
ANC-15   0.915    0.904-1.003         0.2    0.916  0.812-1.021         0.1
Plts-15   0.999    0.994-1.004         0.7    0.999  0.994-1.003         0.7
PS-R > 1   1.043    0.589-1.958         0.9    1.011  0.988-1.168         0.9
Stage-R III/IV   1.597    1.086-1.918      <0.04    1.449  0.999-1.973         0.07
Pre-transplant Rituximab   0.522    0.409-0.906      <0.01    0.845  0.582-1.190         0.5
Abbreviations: Age-R = age at relapse; Extranodal sites-R = extranodal sites at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse; PS = performance status; PS-R = performance status at relapse; stage-r = stage at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic Index at relapse; CR = complete remission; PR = partial response; ALC = absolute lymphocyte count; ANC-15 = absolute neutrophil count at day 15; AMC = absolute monocyte count; and plts-15 = platelets at day 15
Table 4: Multivariate analysis for Overall Survival and Progression-Free Survival.